New kids on the block--step by step to an ideal HCV therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy.Hepatic medicine : evidence and research · 2018
   Review
2. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.World journal of gastroenterology · 2016
   Article
3. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients.Journal of translational medicine · 2016
   Article
4. The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections.Deutsches Arzteblatt international · 2016
   Review
5. Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy.Mediterranean journal of hematology and infectious diseases · 2016
   Review
6. [Specific infections in organ transplantation].Der Internist · 2016
   Review

Corrections and comments

• Comment on
  Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.2015
• Comment on
  Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.2015

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as